Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
- Expected to enroll approximately 4,600 participants with obesity or overweight across two pivotal trials (AURORA-1 and AURORA-2) in the U.S., Europe, and Canada. - Global Phase III clinical program to investigate efficacy and safety of three maintenance doses (20 mg, 40 mg, and 60 mg) over 72 weeks in participants...
Tycoon Group Sustains Profitability: 2026 Interim Results Net Profit Surges 183% Year-on-Year
Business Demonstrates Strong Resilience, Profitability Continues to Materialise Results Highlights Tycoon Group sustained its turnaround success from the previous year, recording a net profit of approximately HK$6.3 million during the Period (1H2025: net loss of approximately HK$7.7 million), representing a year-on-year increase of 182.6% and successfully turning loss into profit compared to the Last Period. During...
INTCO Medical Reports 40.6% H1 2026 Revenue Growth, Expands World’s Largest Disposable Glove Capacity to 107 Billion Pieces
ZIBO, China, Aug. 29, 2026 /PRNewswire/ -- INTCO Medical ("the Company", 300677.SZ), a leading global manufacturer of disposable gloves, reported revenue of RMB 6.91 billion (approx. US$1.03 billion) for the six months ended June 30, 2026, up 40.61% from a year earlier. Net profit attributable to shareholders rose 17.86% to RMB 837.3 million (approx. US$124.6 million). Adjusted net profit attributable...
LifeTech Scientific Corporation Announces 2026 Interim Results
HONG KONG, Aug. 29, 2026 /PRNewswire/ -- LifeTech Scientific Corporation ("LifeTech" or the "Company", together with its subsidiaries, the "Group", stock code: 1302.HK), a medical device company specializing in minimally invasive interventional solutions for cardio-cerebrovascular and peripheral vascular diseases, today announced its unaudited consolidated results for the six months ended 30 June 2026 (the "Reporting Period"). The Group...
Clicklinks | Sanyou Bio Launches Clicklinks, an AI-Driven Innovation Hub for Original Drug Discovery
SHANGHAI, Aug. 28, 2026 /PRNewswire/ -- Sanyou Biopharmaceuticals Co., Ltd. (hereinafter referred to as "Sanyou Bio"), today announced the official launch of Clicklinks, an AI-STAL and SAI-DA powered collaborative network designed to support original drug discovery and preclinical development. Positioned as an Innovation Hub for Original Drug Discovery, Clicklinks brings together industry partners across the biopharmaceutical value chain...
Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers
TSY-110 is positioned to become the first biosimilar alternative to Roche's Kadcyla® (ado-trastuzumab emtansine) in major regulated markets. TAIPEI, Aug. 28, 2026 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (TWSE: 6838), today announced the submission of a Clinical Trial Application (CTA) to European regulatory authorities to conduct a pivotal clinical trial for TSY-110....
HiRO and Differentia Biotech Forge Strategic Alliance to Redefine Clinical Trial Design Through AI-Powered Simulation
Memorandum of Understanding establishes a framework for joint development of clinical trial simulation capabilities The partnership unites global clinical operations excellence with advanced digital twin technology, delivering simulation-first drug development to biotech sponsors navigating an era of compressed timelines and escalating trial costs. SOMERSET, N.J., Aug. 28, 2026 /PRNewswire/ -- At a time when biopharma R&D productivity...
Asieris Pharmaceuticals Releases 2026 Semi-Annual Report: Core Product Commercialization Delivers, Entering a Harvest Period as the Company Accelerates Its Transition to Biopharma
SHANGHAI, Aug. 28, 2026 /PRNewswire/ -- Asieris Pharmaceuticals today released its 2026 Semi-Annual Report, showing comprehensive progress across all business segments. With the gradual realization of commercial launch and international expansion for its core products, the company is accelerating its transition from Biotech to Biopharma: CEVIRA®, the world's first non-invasive treatment for precancerous cervical lesions, has been successfully...
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering
SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced the pricing of its previously announced tranched registered public offering (the "Offering") of (i) 2,580,000 American Depositary...
InxMed Announces Publication in The Lancet Oncology Featuring Encouraging Antitumor Activity of Ifebemtinib in Combination with Garsorasib in Previously Treated Metastatic Colorectal Cancer (CRC) Harboring KRAS G12C Mutation
NANJING, China, Aug. 28, 2026 /PRNewswire/ -- InxMed Co., Ltd ("InxMed"), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical results of ifebemtinib (IN10018), a highly selective focal adhesion kinase (FAK) inhibitor, in combination with garsorasib (D-1553), a potent KRAS G12C inhibitor, in previously treated KRAS G12C-mutant...
